The efficacy of the combined effects of ramucirumab and another anti-PD-L1, durvalumab, in a variety of cancer types including HCC and GC/GEJ was evaluated in a phase 1b study [114]. The gene discussed is CD274; the disease is hepatocellular carcinoma.